Esperion Secures Additional Commercial And Medicare Formulary Coverage For NEXLETOL And NEXLIZET; New Additions To Medicare Formularies At Optum/United AARP And CVS/SilverScript Coupled With Humana Provides Access To More Than 65% Of Medicare Insured Lives And More Than 92% Of Commercially Insured Lives
Portfolio Pulse from Benzinga Newsdesk
Esperion has secured additional commercial and Medicare formulary coverage for its drugs NEXLETOL and NEXLIZET, now covering over 65% of Medicare insured lives and 92% of commercially insured lives. This expanded coverage follows FDA approval of expanded indications, making it easier for healthcare providers to prescribe these non-statin drugs.
September 03, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion's NEXLETOL and NEXLIZET have gained significant additional coverage on Medicare and commercial formularies, now accessible to over 65% of Medicare and 92% of commercially insured lives. This expansion follows FDA approval of expanded indications, potentially boosting sales and market penetration.
The expanded coverage for NEXLETOL and NEXLIZET on major formularies significantly increases the potential market for these drugs. With easier prescribing processes and broader access, sales are likely to increase, positively impacting Esperion's financial performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100